Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
Shanghai, January 5, 2026 – (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into
More